- Complete Ayurvedic Treatment Guide for Leukemia
- Ayurveda’s Role in Leukemia Care
- What Does “Cure” Mean in Leukemia?
- Leukemia Types and Curability
- Why Leukemia Cure Depends on Subtype and Genetics
- Leukemia Remission Explained in Simple Words
- Modern Treatment Options That May Lead to Remission
- Common Treatment Pathways
- When Leukemia Needs Urgent Treatment
- Ayurveda’s Supportive Role in Leukemia Remission Care
- Ayurvedic Goals During Leukemia Care
- Etiology and Risk Factors
- Pathophysiology
- Signs and Symptoms
- Diagnostic Approach
- Complications and Associated Conditions
- References
Leukemia cure is one of the first questions patients and families ask after diagnosis. The honest answer is that some leukemias can enter long-term remission, and some patients may be considered cured after remaining disease-free for many years. However, leukemia is not one disease. The answer depends on leukemia type, genetic markers, age, treatment response, minimal residual disease, relapse risk and access to specialist care.
Leukemia affects the blood and bone marrow. It may cause fatigue, fever, repeated infections, bruising, bleeding, bone pain, swollen lymph nodes, weight loss or abnormal CBC findings. Acute leukemia may progress rapidly and requires urgent hematology care, while some chronic leukemias may be monitored before treatment.
At Panaceayur, Ayurveda is positioned as supervised supportive care, not as a replacement for urgent oncology treatment. Ayurvedic care may support Agni, meaning digestive and metabolic strength; Bala, meaning physical strength; Ojas, meaning vital resilience; appetite, sleep, tissue recovery, treatment tolerance and quality of life.
Complete Ayurvedic Treatment Guide for Leukemia
This article answers an important patient question: can leukemia be cured, and what does remission really mean? For a complete explanation of Ayurvedic treatment planning, classical Ayurvedic understanding, report-based assessment, published integrative evidence, formulation principles, monitoring, diet, safety and consultation preparation, read our detailed pillar guide on Ayurvedic treatment for leukemia.
That pillar article should be used as the main leukemia Ayurveda guide, while this page focuses specifically on cure, remission, relapse risk and treatment decision-making.
Ayurveda’s Role in Leukemia Care
Leukemia is not named as “leukemia” in classical Ayurvedic texts. For clinical interpretation, it may be studied through disorders of Rakta Dhatu, meaning blood tissue; Majja Dhatu, meaning marrow and deeper tissue nutrition; Agni Mandya, meaning weak digestive-metabolic fire; Ama, meaning toxic metabolic residue; and Ojas Kshaya, meaning depletion of vital resilience.
This is an interpretive bridge, not a direct one-to-one classical synonym. Classical Ayurvedic anchors may include Charaka Samhita, Chikitsa Sthana 1 for Rasayana, Chikitsa Sthana 4 for Raktapitta, Chikitsa Sthana 16 for Pandu, and Sushruta Samhita, Nidana Sthana 11 for Granthi-Apachi-Arbuda discussions.
In practical patient care, the Ayurvedic goal should be supportive and individualized. Treatment planning may focus on improving appetite, digestion, sleep, bowel function, strength, tissue nourishment, mucosal comfort, fatigue, treatment tolerance and quality of life.
Because leukemia patients may have anemia, thrombocytopenia, neutropenia, liver enzyme changes, kidney stress, infections or ongoing chemotherapy, targeted therapy or transplant preparation, Ayurvedic medicines must be selected only after reviewing reports and current medications.
What Does “Cure” Mean in Leukemia?
Leukemia cure does not mean the same thing for every patient. In many cancers, doctors use the word remission first. Complete remission usually means blood counts have recovered, symptoms have improved, and leukemia cells are not seen by routine testing.
In leukemia, deeper testing may be needed because a patient can look well but still have measurable residual disease. This is why bone marrow evaluation, flow cytometry, cytogenetics, PCR, next-generation sequencing and MRD monitoring may become important.
For patients, the safest question is not only “Am I cured?” but also:
What type of leukemia do I have?
Am I in complete remission?
Is minimal residual disease detectable?
What is my relapse risk?
Do I need maintenance therapy?
Am I eligible for stem cell transplant or targeted therapy?
Can supportive Ayurveda be safely added with my current treatment?
Leukemia Types and Curability
| Leukemia type | Usual behavior | Cure/remission outlook |
|---|---|---|
| Acute lymphoblastic leukemia | Fast-growing leukemia, common in children but also seen in adults | Many patients can achieve remission; cure depends on age, risk group, MRD and relapse risk |
| Acute myeloid leukemia | Fast-growing leukemia, common in adults | Remission is possible, but relapse risk depends strongly on genetics, age and treatment response |
| Chronic lymphocytic leukemia | Often slow-growing, common in older adults | Many cases are controlled for years; cure is uncommon with routine treatment, but long control is possible |
| Chronic myeloid leukemia | Often driven by BCR-ABL mutation | Targeted therapy can control disease for long periods; deep molecular response may occur in selected patients |
Why Leukemia Cure Depends on Subtype and Genetics
Leukemia treatment is not selected only by symptoms. Two patients may both have “blood cancer,” but their treatment plans may be completely different.
Modern hematology classifies leukemia through cell lineage, speed of disease, genetic markers and molecular behavior. Markers such as BCR-ABL, FLT3, NPM1, TP53, PML-RARA and other mutations may influence treatment choice, relapse risk and prognosis.
Ayurveda adds a different layer of individualized assessment. It evaluates Agni, Bala, Ojas, Prakriti, digestion, sleep, appetite, bowel function, tissue depletion, bleeding tendency, inflammatory signs and tolerance to treatment. This does not replace hematology diagnosis, but it helps personalize supportive care.
Leukemia Remission Explained in Simple Words
Remission means the disease is controlled to a level where signs of leukemia are no longer seen by standard tests. It does not always mean permanent cure.
Types of Remission
Complete Remission
Blood counts improve, symptoms reduce, and leukemia cells are not visible by standard microscopic testing.
Molecular Remission
Sensitive testing does not detect specific molecular disease markers.
MRD-Negative Remission
Minimal residual disease testing does not detect remaining leukemia cells. This is often a stronger sign of treatment response.
Relapsed Leukemia
Leukemia returns after remission.
Refractory Leukemia
Leukemia does not respond adequately to treatment.
Modern Treatment Options That May Lead to Remission
Modern leukemia treatment may include chemotherapy, targeted therapy, immunotherapy, radiation therapy, CAR-T cell therapy, stem cell transplant, clinical trials and supportive care. The selection depends on leukemia subtype, patient age, fitness, genetic markers, disease burden and response to treatment.
Common Treatment Pathways
| Treatment | When it may be used | Purpose |
|---|---|---|
| Chemotherapy | Common in acute leukemia | Reduce or eliminate leukemic cells |
| Targeted therapy | CML, CLL, some AML/ALL cases | Block specific cancer-driving pathways |
| Immunotherapy | Selected ALL, CLL and relapsed cases | Help the immune system attack leukemia cells |
| CAR-T cell therapy | Selected relapsed or refractory cases | Re-engineer immune cells to target leukemia |
| Stem cell transplant | High-risk, relapsed or selected cases | Replace diseased marrow after intensive treatment |
| Supportive care | Throughout treatment | Manage anemia, infections, bleeding, nutrition and side effects |
When Leukemia Needs Urgent Treatment
Acute leukemia may progress quickly and should not be managed casually. Seek urgent medical care if the patient has high fever, severe weakness, breathlessness, uncontrolled bleeding, black stools, confusion, severe headache, repeated infections, very low platelets, very low neutrophils or rapidly rising white blood cell count.
Ayurvedic consultation should never delay urgent diagnosis, chemotherapy, transfusion, antibiotics, antifungal therapy, tumor lysis prevention or transplant preparation when these are medically required.
Ayurveda’s Supportive Role in Leukemia Remission Care
Ayurveda does not describe leukemia by the same modern name. Clinically, it may be interpreted through Rakta Dhatu Dushti, Majja Dhatu involvement, Agni Mandya, Ama accumulation, Ojas Kshaya and Raktavaha-Majjavaha Srotas dysfunction.
It is not a direct classical synonym for leukemia. It is an Ayurvedic framework for understanding blood, marrow, strength, immunity, digestion and systemic depletion.
Ayurvedic Goals During Leukemia Care
| Ayurvedic goal | Patient benefit |
|---|---|
| Support Agni | Better appetite, digestion and nutrient assimilation |
| Build Bala | Improved strength and functional capacity |
| Protect Ojas | Better resilience and recovery support |
| Support Rakta Dhatu | Blood tissue nourishment and recovery support |
| Support Majja Dhatu | Marrow-centered nourishment and deep tissue support |
| Reduce Ama | Better metabolic clarity and digestion |
| Improve sleep and bowel function | Better treatment tolerance and quality of life |
Etiology and Risk Factors
The causes of leukemia are multifactorial, involving a complex interplay of genetic mutations, environmental exposures, and individual susceptibility. While many cases arise spontaneously, several well-established risk factors increase the likelihood of developing leukemia.
A key contributor is chromosomal translocation, notably the t(9;22) abnormality forming the BCR-ABL fusion gene (chemical formula: C₃₀H₃₉N₇O₉P₂S) in chronic myeloid leukemia (CML). This genetic alteration drives uncontrolled proliferation of myeloid cells. Similar mutations affecting genes like FLT3, NPM1, and TP53 are implicated in other leukemia subtypes.
Environmental risk factors include:
- Ionizing radiation exposure (e.g., atomic bomb survivors, therapeutic radiation)
- Benzene exposure (chemical formula: C₆H₆), common in industrial solvents
- Previous chemotherapy, particularly alkylating agents and topoisomerase II inhibitors
- Cigarette smoking (associated with acute myeloid leukemia)
Certain viral infections also contribute:
- Human T-cell leukemia virus (HTLV-1) → Adult T-cell leukemia/lymphoma
- Epstein-Barr virus (EBV) → Linked to some Burkitt lymphoma and leukemic presentations
- Hepatitis viruses and HIV as co-factors in hematologic malignancy risk
Inherited syndromes increase susceptibility:
- Down syndrome: elevated risk for acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia
- Fanconi anemia and Bloom syndrome: increased leukemia risk due to DNA repair defects
From an Ayurvedic perspective, leukemia arises from deep-seated Rakta Dhatu Dushti (vitiation of blood tissue) and Majja Dhatu Kshaya (bone marrow depletion), compounded by chronic Agni Mandya (digestive/metabolic weakness) and Srotas blockage (channel obstruction). Contributory Nidana (causative factors) include:
- Excessive Pitta-aggravating diet (spicy, sour, fermented foods
- Exposure to chemical toxins
- Chronic unresolved mental stress (Manasika Nidana), weakening immune surveillance
- Long-term Viruddha Ahara (incompatible food combinations)
Certain occupational exposures are also highlighted in both systems:
- Ayurveda warns against exposure to metals and chemicals as Rakta Dushti contributors
- Modern data links industrial chemicals to leukemia pathogenesis
Rare or exceptional etiological scenarios include:
- Therapy-related leukemia: secondary leukemia developing 5–10 years after chemotherapy or radiotherapy
- Neonatal leukemia: rare congenital leukemia manifesting within the first month of life
- Chronic low-level benzene exposure leading to leukemia in individuals without industrial contact
Although many risk factors are non-modifiable, awareness of environmental, occupational, and lifestyle contributors provides avenues for prevention and early detection. Both modern and Ayurvedic systems emphasize minimizing exposure to toxins, maintaining healthy digestion, and promoting balanced immune function to reduce leukemia susceptibility.
Pathophysiology
The pathophysiology of leukemia centers on the uncontrolled proliferation of abnormal hematopoietic stem cells within the bone marrow, leading to the accumulation of immature or dysfunctional white blood cells. This clonal expansion interferes with normal blood cell production, causing anemia, thrombocytopenia, and neutropenia—the hallmarks of marrow failure.
At the molecular level, leukemia arises from genetic alterations affecting oncogenes, tumor suppressor genes, and signaling pathways. One of the most well-known examples is the BCR-ABL fusion gene (chemical formula: C₃₀H₃₉N₇O₉P₂S) in chronic myeloid leukemia (CML), formed by the t(9;22) chromosomal translocation. This abnormal gene encodes a constitutively active tyrosine kinase that drives unchecked myeloid proliferation.
Other molecular mechanisms include:
- Mutations in FLT3, NPM1, IDH1/2 in acute myeloid leukemia (AML)
- Chromosomal rearrangements like t(12;21) in acute lymphoblastic leukemia (ALL
- Epigenetic dysregulation and altered transcription factors
The abnormal leukemic cells expand within the marrow, physically crowding out normal hematopoietic cells. This leads to:
- Reduced red blood cell production → anemia
- Reduced platelet production → bleeding tendency
- Impaired neutrophil function → infections
Leukemic cells may spill into the bloodstream, infiltrate organs like the liver, spleen, lymph nodes, central nervous system, and skin, leading to systemic manifestations. In acute leukemias, rapid blast proliferation causes symptoms within weeks, while chronic leukemias may evolve silently over years.
Rare pathophysiological presentations include:
- Leukemia cutis: skin infiltration by leukemic cells causing papules and nodules
- Granulocytic sarcoma (chloroma): extramedullary tumor masses before blood abnormalities
- Aleukemic leukemia: marrow infiltration with absent peripheral blasts
From an Ayurvedic perspective, the underlying pathophysiology of leukemia involves profound disruption of Raktavaha Srotas (channels of blood tissue) and Majjavaha Srotas (bone marrow channels). The derangement of Pitta Dosha, associated with heat, inflammation, and blood tissue abnormalities, plays a dominant role. Concurrent Kapha Dosha imbalance contributes to excessive tissue proliferation and sluggish elimination.
Classical Ayurvedic mechanisms describe:
- Rakta Dushti: qualitative vitiation of blood tissue
- Agni Mandya: reduced metabolic transformation leading to toxic buildup (Ama)
- Ojas Kshaya: depletion of vital energy impairing immunity
- Srotorodha: blockage of bodily channels preventing normal tissue nourishment
The result is an accumulation of pathological tissue (Dushta Rakta) that multiplies abnormally and impairs the function of other Dhatus (tissues). Ayurveda views leukemia as not only a blood disorder but a systemic breakdown of balance across Dosha, Dhatu, Agni, and Srotas.
Understanding the pathophysiology through both modern molecular biology and Ayurvedic systemic dysfunction allows for a more holistic framework. While modern medicine targets molecular drivers with tyrosine kinase inhibitors, immunotherapy, or chemotherapy, Ayurveda aims to restore balance by clearing Ama, rejuvenating Rakta Dhatu, strengthening Agni, and rebuilding Ojas.
This dual perspective supports integrative treatment goals: eliminating abnormal cells while rebuilding the body’s intrinsic capacity for regeneration and defense.
Signs and Symptoms
The clinical presentation of leukemia varies widely, depending on its type, speed of progression, and the degree of bone marrow failure or organ infiltration. Many patients experience vague, nonspecific symptoms that mimic common illnesses, leading to delayed diagnosis. Others present with acute, life-threatening complications.
The most common general symptoms include:
- Fatigue and weakness due to anemia
- Easy uising or bleeding from thrombocytopenia
- Frequent infections from neutropenia
- Fever of unknown origin
- Bone pain or tenderness
- Pale skin (pallor)
In acute leukemia, symptoms typically develop rapidly over days or weeks. Patients may report spontaneous bruising, bleeding gums, nosebleeds, or small purple spots (petechiae) on the skin. Fevers and recurrent infections are common because of a reduced ability to fight pathogens.
Chronic leukemias often progress more slowly, with subtle symptoms that are detected incidentally during routine blood tests. Patients may present with:
- Enlarged lymph nodes
- Abdominal fullness from splenomegaly
- Unintentional weight loss
- Night sweats
Rare or exceptional presentations include:
- Leukemia cutis: infiltration of skin by leukemic cells, appearing as papules or nodules
- CNS involvement: headache, vomiting, cranial nerve palsies
- Granulocytic sarcoma (chloroma): localized tumor mass before blood abnormalities
- Hyperleukocytosis with leukostasis: causing stroke-like symptoms or respiratory distress
Some patients with chronic myeloid leukemia (CML) may enter an accelerated or blast crisis phase, showing acute leukemia-like features after an initial indolent phase.
From an Ayurvedic perspective, many of these symptoms correspond to conditions like Pandu (fatigue, pallor), Raktapitta (spontaneous bleeding), Jwara (fever), and Shotha (swelling). Ayurveda views these signs as evidence of Rakta Dhatu Dushti (blood tissue vitiation), Ojas Kshaya (vitality depletion), and systemic Dosha imbalance.
Additional Ayurvedic symptom correlations include:
- Yellowish or pale skin → Pitta and Rakta imbalance
- Low appetite, bloating → impaired Agni
- Swelling of liver and spleen → obstruction of Raktavaha Srotas
- General debility and mental fatigue → Ojas depletion
In some patients, leukemia’s first sign may be a minor symptom like frequent colds or gum bleeding, masking the underlying marrow dysfunction. Others may have no symptoms initially, with the disease discovered through abnormal lab results.
Clinicians must maintain a high index of suspicion when unexplained cytopenias, persistent fatigue, or unusual infections arise, particularly in individuals with known risk factors or family history.
Recognizing these diverse and sometimes subtle symptoms is critical for early diagnosis, improving outcomes, and guiding both modern and Ayurvedic treatment plans.
Diagnostic Approach
Diagnosing leukemia requires a combination of clinical evaluation, laboratory investigations, and specialized testing to confirm the disease type and guide treatment. While modern diagnostics focus on detecting abnormal cells and genetic mutations, Ayurveda emphasizes functional assessment of the patient’s internal balance.
The first clue often comes from a complete blood count (CBC), showing:
- Anemia (low hemoglobin)
- Thrombocytopenia (low platelets)
- Leukocytosis or leukopenia (high or low white blood cell counts)
- Presence of blasts (immature white cells) in peripheral smear
Peripheral smear examination under microscopy can reveal abnormal cell morphology, helping distinguish between acute and chronic forms. In acute leukemia, numerous blasts may be seen, while chronic leukemia shows mature-appearing but dysfunctional white cells.
Further confirmation requires a bone marrow aspirate and biopsy. This procedure assesses the percentage of blasts in the marrow:
- 20% blasts confirms acute leukemia (according to WHO criteria)
- Variable marrow cellularity in chronic leukemias
Immunophenotyping by flow cytometry is essential to classify the leukemia subtype, using markers such as CD19, CD20, CD3 (lymphoid lineage) or CD13, CD33, MPO (myeloid lineage).
Cytogenetic analysis identifies chromosomal abnormalities like:
- Philadelphia chromosome (t(9;22)) in chronic myeloid leukemia (CML)
- t(12;21) in acute lymphoblastic leukemia (ALL)
- FLT3, NPM1 mutations in acute myeloid leukemia (AML)
Molecular testing with polymerase chain reaction (PCR) and next-generation sequencing can detect minimal residual disease and monitor treatment response.
Other diagnostic tools may include:
- Lumbar puncture to assess central nervous system (CNS) involvement
- Imaging (CT, MRI) for lymphadenopathy, organ infiltration
- Biochemical panels to detect tumor lysis syndrome (↑uric acid: chemical formula C₅H₄N₄O₃, ↑potassium, ↑phosphate)
From an Ayurvedic diagnostic perspective, assessment involves:
- Nadi Pariksha (pulse examination) to detect imbalances in Pitta, Kapha, and Rakta Dhatu
- Observation of skin pallor, tongue coating, nail beds, sclera discoloration
- Inquiry into digestive strength (Agni), bowel habits, mental clarity, and energy levels
- Identifying Srotas (channel) obstruction signs through holistic examination
Rare or exceptional diagnostic scenarios include:
- Aleukemic leukemia: marrow infiltration without peripheral blast elevation
- Chloroma (granulocytic sarcoma): extramedullary mass before blood abnormalities
- Isolated CNS leukemia with normal marrow findings
Early diagnosis is crucial because outcomes improve with prompt treatment initiation. Integrating Ayurvedic insights with modern diagnostics offers a broader understanding, identifying both biochemical abnormalities and functional imbalances contributing to disease progression.
A comprehensive diagnostic approach sets the foundation for personalized, integrative treatment strategies aimed at not only eliminating abnormal cells but also restoring systemic harmony.
Complications and Associated Conditions
Leukemia is not only a disorder of abnormal blood cell production but a condition that disrupts multiple systems, leading to life-threatening complications. These complications arise from both the disease itself and its treatment.
The most common hematologic complications include:
- Severe anemia – fatigue, pallor, dyspnea
- Thrombocytopenia – spontaneous bleeding, petechiae, mucosal hemorrhages
- Neutropenia – recurrent, severe bacterial and fungal infections
Patients with high blast counts may develop hyperleukocytosis, leading to leukostasis—a condition where sluggish, viscous blood impairs microcirculation, causing stroke-like symptoms or respiratory failure.
A hallmark metabolic complication is tumor lysis syndrome, caused by rapid destruction of leukemia cells during treatment, leading to:
- Hyperuricemia (↑ uric acid; chemical formula C₅H₄N₄O₃)
- Hyperkalemia
- Hyperphosphatemia
- Hypocalcemia
This electrolyte imbalance can result in acute kidney injury, cardiac arrhythmias, and seizures.
Central nervous system (CNS) involvement is more common in acute lymphoblastic leukemia (ALL), presenting as headaches, vomiting, cranial nerve palsies, or seizures. In some cases, CNS relapse occurs despite systemic remission, requiring intrathecal chemotherapy.
Extramedullary infiltration may lead to:
- Leukemia cutis: skin lesions from leukemic cell infiltration
- Gum ]hypertrophy: gingival leukemic infiltration in AML
- Granulocytic sarcoma (chloroma): soft tissue tumor mass of myeloid cells
Treatment-related complications add further risk:
- Myelosuppression from chemotherapy → pancytopenia
- Mucositis, nausea, vomiting, diarrhea
- Immunosuppression leading to opportunistic infections
- Cardiotoxicity (e.g., anthracycline-induced)
Rare or exceptional complications include:
- Secondary leukemia following prior chemotherapy or radiation
- Leukoencephalopathy due to intrathecal or high-dose methotrexate
- Chronic graft-versus-host disease post-stem cell transplant
From an Ayurvedic perspective, these complications reflect deep systemic imbalance:
- Ojas Kshaya (depletion of vital essence) explains increased susceptibility to infections
- Raktapitta manifests as spontaneous bleeding tendencies
- Agni Mandya leads to poor digestion and reduced tissue nourishment
- Shotha (swelling) corresponds to organomegaly and lymphadenopathy
Ayurveda views these secondary manifestations as signs of worsening Rakta Dhatu Dushti and impaired Srotas function, requiring a treatment focus on detoxification (Shodhana) and tissue rejuvenation (Rasayana).
Managing leukemia complications involves vigilant monitoring, supportive therapies (transfusions, antibiotics, antifungals), and pre-emptive measures like allopurinol (chemical formula: C₅H₄N₄O) or rasburicase to prevent tumor lysis.
An integrative approach may use Ayurvedic interventions alongside modern care to mitigate chemotherapy side effects, reduce infection risk, and support tissue recovery. Strategies include:
- Herbal support for digestive strength (Agni)
- Rasayana therapies to rebuild Ojas
- Gentle detoxification to remove metabolic waste
Addressing complications holistically improves not only survival but the patient’s overall quality of life, resilience, and long-term health.
All tracking parameters have been removed. PubMed IDs, PMC article numbers, and journal article identifiers have been retained because they are permanent publication identifiers, not tracking IDs.
References
Reference note:
If any reference link does not open because of webpage changes, search using the author name, article title, journal name, PubMed ID, PMCID, or the complete reference in PubMed, PMC, Google Scholar, ScienceDirect, Springer, SAGE, or the journal website.
- Bhishagratna, K. K. (Trans.). (2006). Charaka Samhita (Chikitsa Sthana, Chapter 16: Panduroga Chikitsa, Verses 1–65). Chaukhamba Sanskrit Series Office, pp. 428–445.
- Sharma, P. V. (Trans.). (2009). Sushruta Samhita (Chikitsa Sthana, Chapter 2: Raktapitta Chikitsa, Verses 1–58). Chaukhamba Visvabharati, pp. 95–110.
- Sharma, R. K., & Dash, B. (Trans.). (2010). Bhavaprakasha Nighantu (Rasayana Adhikara, Verses 1–35). Chaukhamba Sanskrit Series, pp. 210–225.
- Pasricha, S. R., Tye-Din, J., Muckenthaler, M. U., & Swinkels, D. W. (2021). Iron deficiency. The Lancet, 397(10270), 233–248.
https://pubmed.ncbi.nlm.nih.gov/33285139/ - Mulik, S. B., & Jha, C. B. (2011). Physicochemical characterization of an iron-based Indian traditional medicine: Mandura Bhasma. Ancient Science of Life, 31(2), 52–57.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3530268/ - Das, S., Das, M. C., & Paul, R. (2012). Swarna Bhasma in cancer: A prospective clinical study. AYU, 33(3), 365–367.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3665104/ - Mishra, A., Kumar, S., & Pandey, A. K. (2013). Scientific validation of the medicinal efficacy of Tinospora cordifolia. The Scientific World Journal, 2013, 292934.
https://pubmed.ncbi.nlm.nih.gov/24453828/ - Tandon, N., & Yadav, S. S. (2020). Safety and clinical effectiveness of Withania somnifera (Linn.) Dunal root in human ailments. Journal of Ethnopharmacology, 255, 112768.
https://pubmed.ncbi.nlm.nih.gov/32201301/ - Chawla, R., Thakur, P., Chowdhry, A., Jaiswal, S., Sharma, A., Goel, R., Sharma, J., Priyadarshi, S. S., Kumar, V., Sharma, R. K., & Arora, R. (2013). Evidence-based herbal drug standardization approach in coping with challenges of holistic management of diabetes: A dreadful lifestyle disorder of the 21st century. Journal of Diabetes & Metabolic Disorders, 12, 35.
https://pubmed.ncbi.nlm.nih.gov/23822656/ - Cancer Research UK. (2024). Chemotherapy for acute myeloid leukaemia.
https://www.cancerresearchuk.org/about-cancer/acute-myeloid-leukaemia-aml/treating-aml/chemotherapy-treatment - Kulala, D. S., Prasad, K., Reddy, P. S., Maruthiyodan, S., Joshi, M. B., Satyamoorthy, K., & Guruprasad, K. P. (2023). Understanding the effects of Abhraka Bhasma on genotoxicity and its DNA repair potential in mouse model. Journal of Ayurveda and Integrative Medicine, 14(2), 100598.
https://pubmed.ncbi.nlm.nih.gov/35973910/ - Paladhi, A., Rej, A., Sarkar, D., Singh, R., Bhattacharyya, S., Sarkar, K., Kar, P., Manna, P. P., & Hira, S. K. (2022). Nanoscale diamond-based formulation as an immunomodulator and potential therapeutic for lymphoma. Frontiers in Pharmacology, 13, 852065.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9014173/ - Bendale, Y. N., Birari-Gawande, P., Patil, A., & Kadam, A. (2024). Ayurveda Rasayana therapy leads to tumor regression and increased survival in chemo-intolerant high-grade stage IV follicular lymphoma: A case study. Clinical Case Reports, 12(6), e8076.
https://pubmed.ncbi.nlm.nih.gov/38827936/ - Du, M., Chen, W., Liu, K., Wang, L., Hu, Y., Mao, Y., Sun, X., Luo, Y., Shi, J., Shao, K., Huang, H., & Ye, D. (2022). The global burden of leukemia and its attributable factors in 204 countries and territories: Findings from the Global Burden of Disease 2019 study and projections to 2030. Journal of Oncology, 2022, 1612702.
https://pubmed.ncbi.nlm.nih.gov/35509847/ - Arnold, J. T. (2023). Integrating Ayurvedic medicine into cancer research programs, part 2: Ayurvedic herbs and research opportunities. Journal of Ayurveda and Integrative Medicine, 14(2), 100677.
https://pubmed.ncbi.nlm.nih.gov/36529638/ - Jung, T., & Cheon, C. (2024). Synergistic and additive effects of herbal medicines in combination with chemotherapeutics: A scoping review. Integrative Cancer Therapies, 23, 15347354241259416.
https://pubmed.ncbi.nlm.nih.gov/38867515/ - Shetti, S., Kumar, C. D., Sriwastava, N. K., & Sharma, I. P. (2012). Pharmacological and therapeutic potential of Asparagus racemosus (Shatavari): A review. Journal of Pharmacognosy and Phytochemistry, 1(4), 32–39.
https://www.phytojournal.com/vol1Issue4/Issue_june_2012/8.1.pdf - Jaiswal, Y. S., & Williams, L. L. (2017). A glimpse of Ayurveda: The forgotten history and principles of Indian traditional medicine. Journal of Traditional and Complementary Medicine, 7(1), 50–53.
https://pubmed.ncbi.nlm.nih.gov/28053888/ - Pal, D., Sahu, C. K., & Haldar, A. (2014). Bhasma: The ancient Indian nanomedicine. Journal of Advanced Pharmaceutical Technology & Research, 5(1), 4–12.
https://pubmed.ncbi.nlm.nih.gov/24696811/ - Vaidya, A. B. (2010). Ayurveda: The original integrative and personalized medicine. Chinese Journal of Integrative Medicine, 16(2), 89–92.
https://link.springer.com/article/10.1007/s11655-010-0080-1
